News Archives - QualityStocks

MondayMar 09, 2026 12:00 pm

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy. Specifically,…

MondayMar 09, 2026 11:15 am

Renewal Fuels Inc. (RNWF) Expands Leadership and Targets 2026 Milestone for Texatron(TM) Fusion Platform

Appointment of fusion researcher Fabrice David adds scientific oversight as commercialization plans advance. Travis Yakimishyn joins as Chief Electrical & Power Systems Officer to lead utility-scale integration. The company is transitioning to American Fusion Inc. following its merger with Kepler Fusion Technologies, with filing and audits nearing completion as the company prepares for SEC reporting status. Management reiterates goal of deploying a 100-megawatt operational unit by year-end 2026, with Kepler‘s plan to sell electricity on a per-kilowatt basis to utilities and industrial customers. Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and…

MondayMar 09, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development

“The EMA's positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO. The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval. Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a…

MondayMar 09, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care. Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring…

MondayMar 09, 2026 9:22 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Management to Participate in March 2026 Investor and Industry Conferences

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and…

MondayMar 09, 2026 9:00 am

Frontieras North America Inc. Is ‘One to Watch’

Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production. The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products. Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility. The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners. Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand. Frontieras North America is an energy and environmental technology company focused…

FridayMar 06, 2026 12:00 pm

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Files Amended Document for Brokered LIFE Offering; Engages AXINO Capital for European Marketing Services

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising. ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties, announced the filing of an amended offering document for its brokered LIFE offering The amendment includes Quebec, site of the company’s rapidly developing Montauban Project, as an offering jurisdiction, with terms remaining the same as previously announced The offering looks to raise gross proceeds of up to C$7,000,600 from the sale of up to 10,295,000 units of the company at C$0.68 a unit ESGold has also engaged AXINO Capital…

FridayMar 06, 2026 11:15 am

GridAI Technologies Corp. (NASDAQ: GRDX) Is Capitalizing on the Data Center and AI-Driven Transformation of the Energy Sector

AI data centers are rapidly increasing electricity consumption, creating new and significant pressures on America’s power infrastructure, with analysts warning that reliable electricity supply could become a defining constraint in global AI competition. Large AI facilities require integrated control of multiple energy assets and market inputs, with real-time monitoring and analytics becoming essential to the management of complex energy systems supporting AI infrastructure. GridAI is developing software to coordinate grid power, on-site generation, battery storage and backup systems for AI data-center campuses. Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge:…

FridayMar 06, 2026 10:30 am

Sparc AI Inc. (CSE: SPAI) (OTC: SPAIF) Positioned to Benefit from Canada’s Defense Industrial Strategy and the Global Shift Toward Sovereign AI Capabilities

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTC: SPAIF) and may include paid advertising. Canada has launched its first Defense Industrial Strategy, unlocking $180 billion in procurement opportunities over 10 years The strategy prioritizes domestic innovation in artificial intelligence, aerospace, and digital technologies Sparc AI’s patented spatial targeting technology and Overwatch navigation platform align with rising demand for advanced software-defined defense systems Sparc AI (CSE: SPAI) (OTC: SPAIF) operates at the nexus of sensor technology, artificial intelligence, and next-generation target acquisition systems, a convergence increasingly integral to modern defense strategy. As global security dynamics shift and allied nations…

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

Site Search

Company Search

Category: News